Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients

Hypoglycemia is the most common side effects for most glucose-lowering therapies. It constitutes a serious risk that faces diabetic patients who fast during Ramadan (the 9th month in the Islamic calendar). New glucose-lowering classes like dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like pep...

Full description

Saved in:
Bibliographic Details
Main Author: Ehab Mudher Mikhael
Format: Article
Language:English
Published: Wiley 2016-01-01
Series:Journal of Diabetes Research
Online Access:http://dx.doi.org/10.1155/2016/6962574
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832561014430760960
author Ehab Mudher Mikhael
author_facet Ehab Mudher Mikhael
author_sort Ehab Mudher Mikhael
collection DOAJ
description Hypoglycemia is the most common side effects for most glucose-lowering therapies. It constitutes a serious risk that faces diabetic patients who fast during Ramadan (the 9th month in the Islamic calendar). New glucose-lowering classes like dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide 1 receptor agonist (GLP-1 RA), and sodium-glucose cotransporter-2 (SGLT-2) inhibitors are efficacious in controlling blood glucose level with less tendency to induce hypoglycemia and thus may constitute a good choice for diabetic patients during Ramadan. This study reviews the safety and efficacy of newer glucose-lowering therapies during Ramadan. This study was accomplished through a careful literature search about studies that assess the benefit and side effects of these new glucose-lowering therapies during Ramadan during September 2015. Vildagliptin, sitagliptin, liraglutide, exenatide, and dapagliflozin were the only studied glucose-lowering therapies. All of the studied newer glucose-lowering therapies except dapagliflozin were associated with reduced risk to induce hypoglycemia. Gastrointestinal upset was common with the usage of liraglutide while increased thirst sensation was common with dapagliflozin. In conclusion DPP-4 inhibitors such as vildagliptin and sitagliptin may form a suitable glucose-lowering therapy option for Ramadan fasting patients.
format Article
id doaj-art-59cad42b5d6547cfa7ee0fcfb72f5f4e
institution Kabale University
issn 2314-6745
2314-6753
language English
publishDate 2016-01-01
publisher Wiley
record_format Article
series Journal of Diabetes Research
spelling doaj-art-59cad42b5d6547cfa7ee0fcfb72f5f4e2025-02-03T01:26:10ZengWileyJournal of Diabetes Research2314-67452314-67532016-01-01201610.1155/2016/69625746962574Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic PatientsEhab Mudher Mikhael0College of Pharmacy, Clinical Pharmacy Department, Baghdad University, Baghdad, IraqHypoglycemia is the most common side effects for most glucose-lowering therapies. It constitutes a serious risk that faces diabetic patients who fast during Ramadan (the 9th month in the Islamic calendar). New glucose-lowering classes like dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide 1 receptor agonist (GLP-1 RA), and sodium-glucose cotransporter-2 (SGLT-2) inhibitors are efficacious in controlling blood glucose level with less tendency to induce hypoglycemia and thus may constitute a good choice for diabetic patients during Ramadan. This study reviews the safety and efficacy of newer glucose-lowering therapies during Ramadan. This study was accomplished through a careful literature search about studies that assess the benefit and side effects of these new glucose-lowering therapies during Ramadan during September 2015. Vildagliptin, sitagliptin, liraglutide, exenatide, and dapagliflozin were the only studied glucose-lowering therapies. All of the studied newer glucose-lowering therapies except dapagliflozin were associated with reduced risk to induce hypoglycemia. Gastrointestinal upset was common with the usage of liraglutide while increased thirst sensation was common with dapagliflozin. In conclusion DPP-4 inhibitors such as vildagliptin and sitagliptin may form a suitable glucose-lowering therapy option for Ramadan fasting patients.http://dx.doi.org/10.1155/2016/6962574
spellingShingle Ehab Mudher Mikhael
Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients
Journal of Diabetes Research
title Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients
title_full Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients
title_fullStr Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients
title_full_unstemmed Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients
title_short Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients
title_sort effectiveness and safety of newer antidiabetic medications for ramadan fasting diabetic patients
url http://dx.doi.org/10.1155/2016/6962574
work_keys_str_mv AT ehabmudhermikhael effectivenessandsafetyofnewerantidiabeticmedicationsforramadanfastingdiabeticpatients